Please select the option that best describes you:
How have you incorporated mirvetuximab into the treatment of platinum-resistant ovarian cancer?
Do you think it works better if incorporated as early as possible in the patient's course, or is it better to "save it" for future recurrences after using all other available regimens?
Answer from: at Community Practice
Related to Q1, this has been on my radar for a couple of years as I was the PI for SORAYA, so I had access to the agent before FDA accelerated approval – now with regular approval. Since the MIRASOL trial demonstrated benefit over standard single agent chemotherapy, it’s preferred if eli...
Sign in or Register to read more
Answer from: at Academic Institution
This question is going to be increasingly important in the current landscape of ovarian cancer management. I have prioritized early ordering of biomarker testing so that I have the test profiles available at recurrence, particularly in the platinum-resistant standpoint.I find that toxicity, pat...